Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

106.95 -0.94 (-0.87%)
Streaming Delayed Price Updated: 12:25 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Behind the Scenes of Moderna's Latest Options Trends
Via Benzinga
Alphabet, Electronic Arts And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by over 90 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
3 Things That Could Help 2023 Loser-Stock Moderna Roar Higher in 2024
Moderna may be heading for a new era of growth. 
Via The Motley Fool
Peering Into Moderna's Recent Short Interest
Via Benzinga
7 Mighty Healthcare Stocks Changing the Game of Medicine
Thanks to the permanent relevance of medical innovations, investors ought to consider looking at these healthcare stocks. 
Via InvestorPlace
3 Struggling Businesses Investors Shouldn't Gamble on This Year
These stocks all crashed heavily in 2023, and there is no reason to expect things will get a whole lot better this year. 
Via The Motley Fool
Critical Insights From Moderna Analyst Ratings: What You Need To Know
Via Benzinga
Smart Money Is Betting Big In MRNA Options
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,700 Today
Via Benzinga
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here. 
Via Benzinga
7 Healthcare Stocks Taking Medicine to the Next Level
With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider. 
Via InvestorPlace
3 Megatrend Stocks that Will Revolutionize Your Portfolio
Consider these powerhouse stocks for likely significant capital appreciation, growth, and rewards for your portfolio. 
Via InvestorPlace
Oxford University Kicks off Human Study for AstraZeneca's COVID-19 Vaccine Technology in Nipah Virus Defense
Join the fight against Nipah virus! Oxford Vaccine Group launches groundbreaking ChAdOx1 NipahB vaccine trial, targeting the deadly virus. 51 participants aged 18-55. Funded by CEPI. Help combat Nipah... 
Via Benzinga
Exposures COVID-19
The Best Places to Invest $100,000 in 2024
Right now looks like a great time to invest in growth stocks. 
Via The Motley Fool
Moderna Stock Is Trading Higher Monday: What's Going On?
Via Benzinga
Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 health care stocks off to strong starts in 2024
With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Your Path to Wealth: 3 Stocks Predicted to Double Your Investment by 2025
Unveil three standout companies set to double investments by 2025 with groundbreaking strategies in tech and healthcare. 
Via InvestorPlace
2024 Marks a New Era Of Pharmaceutical Innovation
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned... 
Via Benzinga
Exposures COVID-19
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
7 S&P 500 Stocks to Buy to Keep the Bull Market Running
The S&P 500 index is approaching a new all-time high and these seven stocks will keep the bull market running. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?
These four names span different sectors, but all underperformed in 2023. Is it time to be a contrarian and pick up bargains on the discount aisle? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
Are defensive sectors ready to outshine growth in 2024?
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead. 
Via MarketBeat
MarketBeat Week in Review – 1/1 - 1/5
Stocks finished the week looking for direction after a hotter-than-expected Jobs report and as investors wait for inflation information and big bank earnings 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.  
Via Benzinga
Exposures Product Safety
Healthcare Champions Kick Off 2024
Surprisingly, it is not Big Tech that kicked off 2024 but healtchare champions. Moderna Inc (NASDAQ: MRNA) shares rose after Oppenheimer upgraded the stock due to the Covid-19 vaccine star possibly... 
Via Benzinga
Exposures COVID-19
Dry January Investing: Trading Pints For Portfolio Growth
Around 15% of Americans said they were planning to participate in Dry January — a month of abstinence from alcohol — according to a survey. 
Via Benzinga
Short Sellers' Nightmare: $195B Evaporates In 2023's Market Surge
Short sellers had a bad year, with bets on the Mag7 tech giants showing the worst losses. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.